Capmatinib efficacy and effects

Capmatinib (Capmatinib) is a new generation of targeted therapy drug. Its main function is to inhibit MET protein kinase. It is widely used in non-small cell lung cancer ( Treatment of patients with METexon14 skipping mutations in NSCLC). The efficacy and role of capmatinib will be discussed in detail below.

1. TargetingMETProtein kinase: METExon14Skipping mutant treatment: The main efficacy of capmatinib lies in its targeting effect on MET exon 14 skipping mutant NSCLC. Abnormal activation of METkinase is closely related to the development and progression of this subtype of lung cancer, and capmatinib inhibits the abnormal activation of the MET pathway and interferes with the growth signals of tumor cells, thus inhibiting tumor development.

2. Improve objective response rate (ORR): significant anti-tumor effect: Clinical trial data showed that capmatinib showed significant objective response rates in patients with exon14skipping mutant NSCLC. After the patient received treatment, the size, number or spread of the tumor was significantly slowed down, providing the patient with effective anti-tumor treatment.

3. Prolonged survival: Improved overall survival of patients: Treatment with capmatinib is also associated with prolonged overall survival (OS) of patients. The drug may help patients control the progression of their disease for longer, thereby improving their overall survival.

4. Controlling disease progression: Effective progression survival (PFS): Capmatinib not only performed well in improving overall survival, but also showed a positive impact on progression survival. After the patient received treatment, the progression of the disease was effectively controlled and the progression of the disease was delayed.

5. Personalized treatment: representative of precision medicine: The application of capmatinib represents an important progress in precision medicine. By based on the patient's tumor genetic variation, capmatinib achieves personalized treatment of METexon14 skipping mutations, allowing patients to obtain treatment options that are more in line with their pathological characteristics.

6. Safety and tolerability: Relatively good safety profile: Although capmatinib has shown significant efficacy in treatment, it has also been concerned about its relatively good safety profile. In clinical trials, capmatinib is generally considered a relatively safe and tolerable drug, especially if patients can effectively manage and mitigate adverse effects.

7. Effects against the cardiovascular system: angiogenesis and tumor invasion: The MET pathway plays an important role in regulating processes such as angiogenesis and tumor invasion. The application of capmatinib can inhibit these processes by blocking the activity of MET kinase, thereby further slowing down the growth and spread of tumors.

In general, capmatinib, as a targeted therapy, has shown significant efficacy in patients with METexon14 skipping mutant NSCLC. Its unique mechanism of action, personalized treatment plan and relatively good safety have made it an important breakthrough in the field of lung cancer treatment, providing patients with a new and promising treatment option. In the future, capmatinib may continue to play a key role in precision medicine and personalized cancer treatment.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.